| 1. |
|
|
| 2. |
- Gimsing, Peter, et al.
(författare)
-
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
- 2010
-
Ingår i: LANCET ONCOLOGY. - : Elsevier Science B.V., Amsterdam.. - 1470-2045 .- 1474-5488. ; 11:10, s. 973-982
-
Tidskriftsartikel (refereegranskat)abstract
- Background Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma. Methods This double-blind, randomised, phase 3 trial was undertaken at 37 clinics in Denmark, Norway, and Sweden. Patients with multiple myeloma who were starting antimyeloma treatment were randomly assigned in a 1:1 ratio to receive one of two doses of pamidronate (30 mg or 90 mg) given by intravenous infusion once a month for at least 3 years. Randomisation was done by use of a central, computerised minimisation system. Primary outcome was physical function after 12 months estimated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire (scale 0-100). All patients who returned questionnaires at 12 months and were still on study treatment were included in the analysis of the primary endpoint. This study is registered with ClinicalTrials. gov, number NCT00376883. Findings From January, 2001, until August, 2005, 504 patients were randomly assigned to pamidronate 30 mg or 90 mg (252 in each group). 157 patients in the 90 mg group and 156 in the 30 mg group were included in the primary analysis. Mean physical function at 12 months was 66 points (95% CI 62.9-70.0) in the 90 mg group and 68 points (64.6-71.4) in the 30 mg group (95% CI of difference -6.6 to 3.3; p=0.52). Median time to first skeletal-related event in patients who had such an event was 9.2 months (8.1-10.7) in the 90 mg group and 10-2 months (7.3-14.0) in the 30 mg group (p=0.63). In a retrospective analysis, eight patients in the pamidronate 90 mg group developed osteonecrosis of the jaw compared with two patients in the 30 mg group. Interpretation Monthly infusion of pamidronate 30 mg should be the recommended dose for prevention of bone disease in patients with multiple myeloma.
|
|
| 3. |
- Gregersen, Henrik, et al.
(författare)
-
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
- 2022
-
Ingår i: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 108:1, s. 34-44
-
Tidskriftsartikel (refereegranskat)abstract
- Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods This randomised, open-label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re-induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 -> 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86). Results Median time to progression (TTP) after randomisation was 25.1 months (22.5-NR) in the carfilzomib-dexamethasone maintenance group and 16.7 months (14.4-21.8) in the control group (HR 0.46, 95% CI 0.30-0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections. Conclusion In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well-tolerated with manageable toxicity.
|
|
| 4. |
- Mellqvist, Ulf-Henrik, et al.
(författare)
-
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
- 2013
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 121:23, s. 4647-4654
-
Tidskriftsartikel (refereegranskat)abstract
- The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks or no consolidation. The hypothesis was that consolidation therapy would prolong progression-free survival (PFS). The PFS after randomization was 27 months for the bortezomib group compared with 20 months for the control group (P = .05). Fifty-one of 90 patients in the treatment group compared with 32 of 90 controls improved their response after randomization (P = .007). No difference in overall survival was seen. Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires, whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for patients not achieving at least a very good partial response (VGPR) but not for patients in the andgt;= VGPR category at randomization. Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at www.clinicaltrials.gov as #NCT00417911.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Schmitz, Alexander, et al.
(författare)
-
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission : results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
- 2022
-
Ingår i: BMC Cancer. - : BMC. - 1471-2407. ; 22:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments. Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitdudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression. Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with >= 3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease and clinical progression by 5.5 months and 12.6 months (mean values), respectively. Mean malignant plasma cells doubling time for the six patients was 1.8 months (95% CI, 1.4-2.3 months). Minimal malignant plasma cells detection limit was 4 x 10-5. Conclusions: Flow-MRD is a sensitive method for longitudinal monitoring of minimal residual disease dynamics in multiple myeloma patients in complete response. Increasing minimal residual disease levels precedes biochemically assessed changes and is an early indicator of subsequent clinical progression.
|
|
| 8. |
|
|
| 9. |
-
Design and disorder : perspectives from science and theology
- 2002
-
Samlingsverk (redaktörskap) (övrigt vetenskapligt/konstnärligt)abstract
- Artiklarna i denna antologi belyser hur nutida forskningsrön och vetenskaplig diskussion om frågor som kaos och komplexitet, förutsägbarhet och kausalitet, emergens och ordning påverkar traditionella religiösa och vetenskapliga tankar om oförutsägbarhet, slump, ändamål och skapelse. Teologer och naturvetare från sekulär, protestantisk, katolsk och ortodox tradition visar hur ordning och oordning hänger samman och tilllsammans utgör förutsättning för livets framväxt och utveckling, och hur komplexitet, instabilitet och förgänglighet utgör en källa för teologisk reflexion. Bidragen i denna bok är i huvudsak föredrag och ett urval av papers som presenterades vid ESSSATs (European Society for the Study of Science and Theology) konferens i Lyon våren 2000.
|
|
| 10. |
|
|
| 11. |
- Ginés, Laia, et al.
(författare)
-
Time-bin entangled photon pairs from quantum dots embedded in a self-aligned cavity
- 2021
-
Ingår i: Optics Express. - 1094-4087. ; 29:3, s. 4174-4180
-
Tidskriftsartikel (refereegranskat)abstract
- We introduce a scalable photonic platform that enables efficient generation of entangled photon pairs from a semiconductor quantum dot. Our system, which is based on a self-aligned quantum dot- micro-cavity structure, erases the need for complex steps of lithography and nanofabrication. We experimentally show collection efficiency of 0.17 combined with a Purcell enhancement of up to 1.7. We harness the potential of our device to generate photon pairs entangled in time bin, reaching a fidelity of 0.84(5) with the maximally entangled state. The achieved pair collection efficiency is 4 times larger than the state-of-the art for this application. The device, which theoretically supports pair extraction efficiencies of nearly 0.5 is a promising candidate for the implementation of bright sources of time-bin, polarization- and hyper entangled photon pairs in a straightforward manner.
|
|
| 12. |
- Görman, Ulf, et al.
(författare)
-
A Current Swedish Survey on Attitudes to Science-and-Religion
- 2002
-
Ingår i: Studies in science and theology : yearbook of the European society for the study of science and theology. - 8798774131 ; 8, s. 341-350
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Artikeln presenterar resultat från en enkätundersökning bland 2000 personer bosatta i Sverige. I enkäten ställdes bland annat frågor om synen på förhållandet mellan naturvetenskap och religion. Resultaten ger vid handen att man uppfattar naturvetenskap och religion som kompletterande varandra, och att denna uppfattning är vanligare med högre utbildning. Uttalade ateister uppfattar i hög utsträckning relationen naturvetenskap–religion som präglad av konflikt eller kontaktlöshet. Endast en minoritet har påverkats i sin religiösa tro av nyheter i naturvetenskaperna.
|
|
| 13. |
- Görman, Ulf, et al.
(författare)
-
Introduction
- 2002
-
Ingår i: Design and disorder : perspectives from science and theology. - 0567088685 ; , s. 1-10
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Artikeln introducerar bokens tematik. Några exempel: I traditionell kristen skapelsetro manifesteras Guds godhet genom ordning, medan kaos, synd och död är uttryck för onda makter. Också vetenskapen uppfattar traditionellt verkligheten som ordnad i betydelsen regelbunden. Aktuella trender i såväl vetenskap som teologi utmanar dessa tolkningar. Kaosteori visar att vår traditionella tolkning av såväl deteminism som slump är alltför begränsad. Vad betyder detta för religiösa föreställningar om Guds försyn, förutvetande och predestination? Behöver teologin integrera föreställningar om slump? Artikeln diskuterar vidare om design är en egenskap hos verkligheten eller betraktaren, och om ordning med nödvändighet är harmonisk. Biologer har traditionellt avvisat föreställningar om intentionalitet men accepterat tanken på funktion. Men hur långt ifrån varandra ligger egentligen funktion, design, intentionalitet och teleologi?
|
|
| 14. |
- Jendle, Johan, 1963-, et al.
(författare)
-
Late-onset familial neurohypophyseal diabetes insipidus due to a novel mutation in the AVP gene
- 2012
-
Ingår i: Clinical Endocrinology. - Hoboken, USA : Wiley-Blackwell. - 0300-0664 .- 1365-2265. ; 77:4, s. 586-592
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Familial neurohypophyseal diabetes insipidus (FNDI) is mainly an autosomal dominant inherited disorder presenting with severe polydipsia and polyuria in early childhood. In this study, we aimed to determine the molecular genetics and clinical characteristics of a large Swedish-Norwegian family presenting with very late-onset autosomal dominant FNDI.Patients: Six probands with a history of developing polyuria and polydipsia during adolescence were studied.Measurements: Information on family demography was collected by personal interview with family members. The genetic cause of FNDI was identified by DNA sequencing analysis of the coding regions of the AVP gene. The clinical characteristics were determined by the measurement of basal urine production and osmolality as well as by measurements of concurrent levels of plasma AVP, plasma osmolality, and urine osmolality during fluid deprivation and bolus injection of DDAVP. The integrity of the neurohypophysis was evaluated by magnetic resonance imaging.Results: The mean age of encountering the first clinical symptoms in the family was 14·8 years (range 3-30 years) (n = 17). All six affected subjects investigated were heterozygous for a novel mutation in the AVP gene (g.1848C>T) predicting a p.Pro84Leu substitution in the AVP precursor protein. We found partial deficiency in evoked AVP secretion during fluid deprivation in one subject and complete deficiency in another. The pituitary bright spot was absent in all six affected subjects studied.Conclusion: A novel mutation in the AVP gene predicted to cause a neurophysin II dimerization defect is causing surprisingly late onset of FNDI in a large, six generation, Swedish-Norwegian family. The mutation is associated with both complete and partial deficiency in evoked AVP secretion during fluid deprivation in patients who have suffered from FNDI for decades.
|
|
| 15. |
- Jurkat, Jonathan, et al.
(författare)
-
Technological implementation of a photonic Bier-Glas cavity
- 2021
-
Ingår i: Physical Review Materials. - 2475-9953. ; 5:6
-
Tidskriftsartikel (refereegranskat)abstract
- In this paper, we introduce a quantum photonic device, which we term the photonic Bier-Glas cavity. We discuss its fabrication and functionality, which is based on the coupling of integrated In(Ga)As quantum dots to a broadband photonic cavity resonance. By design, the device architecture uniquely combines the Purcell enhancement of a photonic micropillar structure with a broadband photonic mode shaping of a vertical, tapered waveguide, making it an interesting candidate to enable the efficient extraction of entangled photon pairs. We detail the epitaxial growth of the heterostructure as well as the necessary lithography steps to approach a GaAsbased photonic device with a height exceeding 15 mu m, supported on a pedestal that can be as thin as 20 nm. We further describe its key performance parameters using a Fourier-modal method. Finally, we present an optical characterization, which confirms the presence of broadband optical resonances, in conjunction with amplified spontaneous emission of single photons.
|
|
| 16. |
- Leidenhag, Sven Mikael, 1986-
(författare)
-
Naturalizing God? : A Critical Evaluation of Religious Naturalism
- 2016
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- This thesis seeks to critically evaluate religious naturalism as a position in the dialogue between science and religion. I seek to explicate the major topics of debate within religious naturalism (chapter 2), as well as the naturalistic and religious aspects of religious naturalism. It is argued that religious naturalists express reductive as well as non-reductive understandings of naturalism (chapter 3), which I refer to as monistic naturalism and pluralistic naturalism, respectively. It is argued that monistic naturalism cannot account for several important beliefs, regarding agency, intentionality, and semantic normativity. Pluralistic naturalism, although more promising, seems to invite dualism (chapter 4). Another metaphysical framework is, therefore, needed and several alternatives are explored in chapters 7-9. Chapter 5 outlines the religious aspects of religious naturalism. It is shown that religious naturalists express realistic, anti-realistic, and pragmatic understandings of religious discourse. These ways of understanding religion are critically evaluated (chapter 6). Given some of the problems encountered in previous chapters, I propose three alternative frameworks for articulating religious naturalism.First, I outline and evaluate possible naturalistic solutions (chapter 7), including liberal naturalism, agnostic naturalism and pragmatic naturalism, and how they may help religious naturalism in moving forward. It is argued that both liberal naturalism and agnostic naturalism encounter the problem of competing ontologies. That is, it remains unclear why we should prefer a naturalistic ontology over non-naturalistic ontologies. Pragmatic naturalism is critiqued for reducing philosophical issues to linguistic agreements between speakers.Second, I evaluate two possible theistic frameworks: panentheism and Fiona Ellis’ attempt to fuse naturalism with theism (chapter 8). I suggest that panentheism fails to avoid dualism, and that the theistic dimension of Ellis’ proposal remains unclear. Hence, these forms of theism cannot aid religious naturalism, and instead we must turn to a third alternative framework.Third, I propose panpsychism as the final and most promising framework (chapter 9). According to panpsychism, mind-properties are widespread and every physical entity has an experiential dimension to it. It is argued that panpsychism carries metaphysical, eco-ethical, as well as religious benefits. Panpsychism, therefore, can help religious naturalism in moving forward.
|
|
| 17. |
- Olsen, Rikke K J, et al.
(författare)
-
ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.
- 2007
-
Ingår i: Brain : a journal of neurology. - : Oxford University Press (OUP). - 1460-2156. ; 130:Pt 8, s. 2045-54
-
Tidskriftsartikel (refereegranskat)abstract
- Multiple acyl-CoA dehydrogenation deficiency (MADD) is a disorder of fatty acid, amino acid and choline metabolism that can result from defects in two flavoproteins, electron transfer flavoprotein (ETF) or ETF: ubiquinone oxidoreductase (ETF:QO). Some patients respond to pharmacological doses of riboflavin. It is unknown whether these patients have defects in the flavoproteins themselves or defects in the formation of the cofactor, FAD, from riboflavin. We report 15 patients from 11 pedigrees. All the index cases presented with encephalopathy or muscle weakness or a combination of these symptoms; several had previously suffered cyclical vomiting. Urine organic acid and plasma acyl-carnitine profiles indicated MADD. Clinical and biochemical parameters were either totally or partly corrected after riboflavin treatment. All patients had mutations in the gene for ETF:QO. In one patient, we show that the ETF:QO mutations are associated with a riboflavin-sensitive impairment of ETF:QO activity. This patient also had partial deficiencies of flavin-dependent acyl-CoA dehydrogenases and respiratory chain complexes, most of which were restored to control levels after riboflavin treatment. Low activities of mitochondrial flavoproteins or respiratory chain complexes have been reported previously in two of our patients with ETF:QO mutations. We postulate that riboflavin-responsive MADD may result from defects of ETF:QO combined with general mitochondrial dysfunction. This is the largest collection of riboflavin-responsive MADD patients ever reported, and the first demonstration of the molecular genetic basis for the disorder.
|
|
| 18. |
- Stenmark, Mikael, 1962-, et al.
(författare)
-
Naturalism and Beyond : Religious Naturalism and Its Alternatives
- 2016
-
Bok (refereegranskat)abstract
- This book offers a critical analysis of the varieties of contemporary naturalism - from scientific naturalism to religious naturalism. What are the claims of naturalism apart from its denial of 'the supernatural'? What are the distinctive modes of thought within contemporary religious naturalism? Some argue for a science-based worldview, others for a cosmic view of reality that includes human engagement and religious commitment - with or without God-talk.The book shows how an appeal to what is beyond empirically validated facts resurfaces within most varieties of naturalism. But it also points to the fact that immanentist frameworks are widely presupposed among contemporary theologians who do not describe themselves as 'naturalists'. Rival positions and conflicts of interpretations emerge as to the question of transcendence and the Beyond, and different philosophical theologies are at work - from the strict denial of theism to ground-of-being-theisms to classic and alternative views of the divine.
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
- Wirén, Jakob, et al.
(författare)
-
Wingren and the Theology of Religions : Inter-Religious Hermeneutics
- 2017
-
Ingår i: Reformation Theology for a Post-Secular Age : Løgstrup, Prenter, Wingren, and the Future of Scandinavian Creation Theology - Løgstrup, Prenter, Wingren, and the Future of Scandinavian Creation Theology. - Göttingen : Vandenhoeck & Ruprecht. - 2198-7556. - 9783525604588 - 9783666604584 ; 24, s. 215-226
-
Bokkapitel (refereegranskat)
|
|
